All In Biotech

Drug Trial Radar · NCT00522379

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Oct 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 514 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

514

Actual

Start

Jul 2007

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Aug 29, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.

Conditions

  • Parkinson's Disease

Interventions

  • RotigotineDrug

    2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks

  • RotigotineDrug

    4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks

  • PlaceboOther

    Placebo transdermal patch applied daily

  • RotigotineDrug

    6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks

  • RotigotineDrug

    8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily DiaryTime frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

Locations

77 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Tuscaloosa, Alabama

  • Site not named

    Gilbert, Arizona

  • Site not named

    Peoria, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Fountain Valley, California

  • Site not named

    Fresno, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    Loma Linda, California

  • Site not named

    Oxnard, California

  • Site not named

    Aurora, Colorado

  • Site not named

    New Haven, Connecticut

  • Site not named

    Boca Raton, Florida

  • Site not named

    Bradenton, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Naples, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Ormond Beach, Florida

  • Site not named

    Pompano Beach, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Sunrise, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    Suwanee, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Anderson, Indiana

  • Site not named

    Des Moines, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Southfield, Michigan

  • Site not named

    Golden Valley, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Missoula, Montana

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.